SLXN Silexion Therapeutics Corp - 8-K

Item 8.01 Other Events.

Further to its previous reports, as well as the approval of its shareholders received on May 5, 2026, on May 26,
2026, Silexion Therapeutics Corp, a Cayman Islands exempted company (“ Silexion ” or the “ Company ”) issued a press release announcing a prospective 1-for-10 reverse share split of all of its issued and outstanding, and authorized but unissued, ordinary shares. The reverse share split will
become effective after the close of the market on May 28, 2026, and the Company’s ordinary shares will begin trading on a reverse split-adjusted basis on the Nasdaq Capital Market at the open of the market on May 29, 2026. The ticker symbol for the
ordinary shares will remain “SLXN.”

The reverse share split will be effected automatically, without any action required on the part of the Company’s
shareholders. The reverse share split will result in a corresponding increase in the par value of the Company’s ordinary shares, from $0.0135 per share to $0.135 per share. No fractional shares will be issued as a result of the reverse share split,
as any fractional share totals as to which shareholders who are DTC participants become entitled will be rounded up to the nearest whole number of shares. A copy of the press release announcing the reverse share split is attached as Exhibit 99.1 to
this report and is incorporated herein by reference.

Item 9.01   Financial Statements and Exhibits

(d) Exhibits

99.1

Press Release dated
May 26, 2026